Provention Bio

Provention Bio Net Tangible Assets

Delisted

The Net Tangible Assets of Provention Bio (PRVB) as of Oct 25, 2026 is 62.29 M USD. In the previous year, Net Tangible Assets was -292.07 M USD — a change of -121.33% (higher).

Net Tangible Assets

62.29 MUSD

YoY

-121.33%

Last updated:

Net Tangible Assets of Provention Bio is 2022 62.29 M USD. Net Tangible Assets of Provention Bio was 2021 -292.07 M USD. It decreases by -121.33% higher compared to the previous year.

The Provention Bio Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2016
-164,707.00 USD
Jan 1, 2017
20.15 M USD
Jan 1, 2018
59.66 M USD
Jan 1, 2019
-79.06 M USD
Jan 1, 2020
-177.64 M USD
Jan 1, 2021
-292.07 M USD
Jan 1, 2022
62.29 M USD
The Provention Bio Net Tangible Assets history
YEARNet Tangible AssetsYoY
62.29 MUSD-121.33%
-292.07 MUSD+64.42%
-177.64 MUSD+124.69%
-79.06 MUSD-232.52%
59.66 MUSD+196.05%
20.15 MUSD-12,334.75%
-164,707.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Provention Bio Stock analysis

What does Provention Bio do? Provention Bio Inc is a US biotechnology company specializing in the development of preventive therapies for autoimmune diseases and other chronic conditions. The company was founded in 2016 by a group of experienced biotech managers and has its headquarters in Oldwick, New Jersey. The history of Provention Bio begins with the recognition that many current treatments for autoimmune diseases such as type 1 diabetes, celiac disease, and lupus only aim to treat the symptoms of the disease rather than addressing their causes. Therefore, the company is committed to developing innovative and preventive therapies that directly target the causes of autoimmune diseases. Provention Bio's business model is based on sourcing and developing new therapies through to commercialization. The company is dedicated to early-stage research and development and works closely with academic institutions, government agencies, and other companies to achieve its goals. Additionally, Provention Bio invests in clinical trials to prove the efficacy of its therapies and ensure their approval by regulatory authorities. The various divisions of Provention Bio encompass some of the most important autoimmune diseases currently lacking effective cures. These include type 1 diabetes, celiac disease, lupus, MS, and other rare autoinflammatory diseases. Provention Bio's products aim to regulate the immune system and enhance the body's self-healing by influencing biological processes. One of Provention Bio's key products is Teplizumab, a preventive medication for the treatment of type 1 diabetes. The company has acquired the exclusive global rights to this medication, relying on promising results from its clinical trials. Since its FDA approval in 2021, the medication has filled an important market need. Additionally, Provention Bio has several other potential therapies in its pipeline. Among them is PRV-3279, a medication specifically developed for the treatment of celiac disease, currently in phase 2 clinical trials. Additionally, Teplizumab is being investigated for use in other autoimmune diseases such as lupus and MS. The goal of Provention Bio is to positively impact the quality of life and health of millions of people worldwide. The company is working hard to develop innovative preventive therapy approaches that focus on the causes of autoimmune diseases rather than just treating the symptoms. In doing so, Provention Bio is a significant addition to the wide range of existing treatment options by significantly expanding therapeutic choices. In summary, Provention Bio Inc is considered an emerging biotechnology company with great potential in the preventive treatment of autoimmune diseases. The company has a promising pipeline of therapies that have the potential to improve the lives of millions of people worldwide. The company aims to develop preventive and effective therapies that directly address the causes of autoimmune diseases. Provention Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Provention Bio stock

Net Tangible Assets of Provention Bio is 62.29 M USD in 2022.

Net Tangible Assets of Provention Bio changed from -292.07 M USD to 62.29 M USD, representing a -121.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets Provention Bio since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's Provention Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Provention Bio

All Key Metrics — Provention Bio